Doroudi Maryam, Pinsky Paul F, Marcus Pamela M
Division of Cancer Prevention, National Cancer Institute, Bethesda, MD.
Division of Cancer Control and Population Sciences, National Cancer Institute, Bethesda, MD.
JNCI Cancer Spectr. 2018 Sep 18;2(3):pky042. doi: 10.1093/jncics/pky042. eCollection 2018 Jul.
The Lung Screening Study was a multicenter controlled feasibility trial that randomly assigned subjects to undergo two rounds of screening with either low-dose spiral computed tomography (LDCT) or chest X-ray (CXR). Long-term follow-up was performed to evaluate any differences in lung-cancer-specific and all-cause mortality between arms. In 2000, subjects were randomly assigned at six screening centers. Linkage with the National Death Index was performed to ascertain long-term mortality for subjects. Median follow-up for mortality of the 1660 and 1658 subjects randomly assigned to LDCT and CXR, respectively, was 5.2 years. There were 32 and 26 deaths from lung cancer in the two groups, respectively, corresponding to lung cancer death rates of 3.84 and 3.10 per 1000 person-years, and a risk ratio of 1.24 (95% confidence interval = 0.74 to 2.08). The risk ratio for all-cause mortality was 1.20 (95% confidence interval = 0.94 to 1.54). These findings can contribute to the overall knowledge on LDCT lung cancer screening.
肺癌筛查研究是一项多中心对照可行性试验,该试验将受试者随机分为两组,分别接受两轮低剂量螺旋计算机断层扫描(LDCT)或胸部X光(CXR)筛查。进行长期随访以评估两组之间肺癌特异性死亡率和全因死亡率的差异。2000年,在六个筛查中心对受试者进行了随机分组。与国家死亡指数进行关联以确定受试者的长期死亡率。随机分配到LDCT组和CXR组的1660名和1658名受试者的死亡率中位随访时间为5.2年。两组分别有32例和26例肺癌死亡,对应肺癌死亡率分别为每1000人年3.84例和3.10例,风险比为1.24(95%置信区间=0.74至2.08)。全因死亡率的风险比为1.20(95%置信区间=0.94至1.54)。这些发现有助于增进对LDCT肺癌筛查的整体认识。